A New Phase 3 Clinical Trial for Colorectal Cancer
Fox Chase Cancer Center is conducting a phase 3 clinical trial using pembrolizumab for patients with MSI‑H or dMMR metastatic colorectal cancer.
The blog post announces a Phase 3 clinical trial at Fox Chase Cancer Center evaluating the efficacy of pembrolizumab, an anti‑PD‑1 antibody, in patients with MSI‑H or dMMR stage IV colorectal cancer. The study aims to determine whether pembrolizumab improves progression‑free survival compared to standard chemotherapy and to identify biomarkers of response.
This trial could expand treatment options for MSI‑H/dMMR colorectal cancer patients, a subset that has limited curative choices in metastatic disease, and may provide insight into immune checkpoint therapy across other solid tumors.
Bizonyítékszint: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Kapcsolódó jelek
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E‑Mutated Colorectal Cancer
- Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
- Three Versus 6 Months of Adjuvant Oxaliplatin‑Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics